Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA) (LuTK03)
A Phase 3, Multicenter, Randomized, Controlled, Open-Label Clinical Trial of Aglatimagene Besadenovec (CAN-2409) Plus Prodrug and Pembrolizumab Versus Docetaxel for Stage IV Non-Squamous Non-Small Cell Lung Cancer Progressing on Pembrolizumab-based Treatment
調査の概要
状態
条件
詳細な説明
PRIMARY OBJECTIVE:
I. To compare overall survival (OS) in participants previously treated with platinum-based chemotherapy and pembrolizumab-based immunotherapy for stage IV non-squamous, non-small cell lung cancer (NSCLC) randomized to pembrolizumab and aglatimagene plus prodrug (valacyclovir) versus standard of care docetaxel chemotherapy.
SECONDARY OBJECTIVES:
I. To compare patient-reported outcomes (PRO) between participants treated with aglatimagene besadenovec + prodrug in combination with pembrolizumab versus SoC docetaxel chemotherapy.
II. To evaluate the safety of aglatimagene besadenovec + prodrug in combination with pembrolizumab versus SoC docetaxel chemotherapy.
OUTLINE: Patients are randomized to 1 of 2 arms. ARM 1: Patients receive two aglatimagene intratumoral injections followed by oral prodrug and pembrolizumab IV on study.
ARM 2: Patients receive docetaxel chemotherapy per standard of care on study.
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
New York
-
New York、New York、アメリカ、10016
- 募集
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health
-
主任研究者:
- Daniel Sterman, MD
-
コンタクト:
- Daniel Sterman, MD
- 電話番号:212-263-8865
- メール:Daniel.Sterman@nyulangone.org
-
コンタクト:
- NYU Langone Health ClinicalTrials.gov Administrators
- メール:Ct.gov@nyulangone.org
-
-
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
説明
Inclusion Criteria:
- Age ≥ 18 years, at the time of signing the informed consent.
- Histologically confirmed metastatic Stage IV non-squamous NSCLC.
Measurable disease per RECIST v1.1 with at least 1 thoracic lesion amenable to intratumoral injection (e.g., pathological lymph node or lung lesion).
Note: Able to be reached by bronchoscopy (including robotic bronchoscopy or flexible bronchoscopy with or without endobronchial ultrasound), or by percutaneous injection.
Documented radiographic progression observed in at least 3 consecutive scans or according to RECIST v1.1 criteria after a minimum of 12 weeks on continued pembrolizumab, determined by central review.
Note: Participants on a pembrolizumab-based regimen should have achieved a best overall response (BOR) of at least SD (e.g., participants with a BOR of PD while on pembrolizumab are not eligible).
Prior treatment requirements:
- Must have received platinum-based chemotherapy in any line of therapy.
- May have received pembrolizumab therapy in combination with chemotherapy or sequentially. Note: The participant must be currently progressing on pembrolizumab or a pembrolizumab-based regimen.
- ECOG performance status of 0 or 1 at screening.
Has adequate bone marrow function, defined as:
- Platelet count ≥ 75,000/mm3.
- Hemoglobin ≥ 9.0 g/dL (
- Absolute neutrophil count (ANC) ≥ 1500/mm3
Has adequate organ function, defined as: a) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 ×upper limit of normal (ULN); (≤ 5.0 × ULN if transferase elevation is due to liver metastases) AND b) Total bilirubin ≤ 1.5 × ULN (< 3.0 × ULN in the presence of documented Gilbert's syndrome [unconjugated hyperbilirubinemia] or liver metastases at baseline). c) Creatinine clearance ≥ 30 mL/min as calculated using the Cockcroft-Gault equation). d) International normalized ratio (INR) < 1.5 without anticoagulants, INR < 3 if on prophylactic anticoagulation therapy.
e) Prothrombin time (PT) and either partial thromboplastin (PTT) or activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN.
Completion of prior therapy with required washout and recovery:
- Cytotoxic chemotherapy: > 14 days from the last dose.
- Monoclonal antibodies (e.g., bevacizumab, ramucirumab): ≥ 5 half-lives or ≥ 42 days, whichever is longer.
- Recovered to ≤ Grade 1 from prior therapy-related clinical toxicities (except alopecia and stable endocrine replacement).
- Projected life expectancy ≥ 12 weeks (or 3 months) in the opinion of the Investigator.
- Pregnancy test (for females of childbearing potential) negative at screening.
- Male and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception.
Exclusion Criteria:
Participants meeting any exclusion criteria for this trial will be disqualified from entering the study.
- Has a known actionable genomic alteration, including EGFR, ALK, or ROS1 rearrangements, for which approved targeted therapy exists. Participants who are receiving or have previously received tyrosine kinase inhibitor (TKI) therapy targeting EGFR, ALK, or ROS1 are excluded.
- Prior therapy with docetaxel either as monotherapy or in combination with other agents.
- Prior treatment with CTLA-4 inhibitor (e.g., ipilimumab).
- History of severe irAEs related to ICI.
- Has a known history of active autoimmune disease requiring systemic immunosuppressive therapy within the past 2 years is excluded. Note: Participants receiving physiologic corticosteroid replacement (e.g., ≤ 10 mg/day prednisone equivalent) are eligible.
- History of hypersensitivity or allergic reactions to valacyclovir.
- Active, uncontrolled, clinically significant bacterial, fungal, or viral infection, or any ongoing infection requiring systemic therapy.
- Clinically active central nervous system (CNS) metastases or leptomeningeal disease. Evidence of new or progression of CNS confirmed by imaging during the study screening.
- Persistently symptomatic bone metastases.
- Has liver metastases involving more than half of the liver.
- Prior radiotherapy within 2 weeks of the start of the study drug.
- Has a known history of active interstitial lung diseases (ILD) (≥ grade 2) or noninfectious pneumonitis requiring active therapy, or for whom suspected ILD/pneumonitis cannot be ruled out by imaging at screening, or clinically severe pulmonary compromise due to intercurrent pulmonary illness and/or pulmonary disorder (e.g., severe chronic obstructive pulmonary disease, restrictive lung disease, etc.) requiring supplemental oxygen (>2L/min at rest) or any autoimmune, connective tissue or inflammatory disorders with active pulmonary involvement (i.e., rheumatoid arthritis, Sjogren's syndrome, sarcoidosis, etc.), or any prior pneumonectomy.
- Receiving or anticipated to receive investigational agents or has used an investigational device within 4 weeks prior to the first dose of study drug.
- Ongoing clinically significant toxicity (> Grade 2 except alopecia), associated with prior treatment including systemic therapy, radiotherapy, or surgery.
- Has a known history of Human Immunodeficiency Virus (HIV) infection and/or acquired immunodeficiency syndrome (AIDS)-related illness.
- Has a known active or known prior history of Hepatitis B (HBV) infection (e.g., hepatitis B virus surface antigen [HBsAg] reactive or detectable quantitative levels of HBV DNA) or known active Hepatitis C (HCV) (e.g., hepatitis C virus RNA [quantitative] is detected).
Has an uncontrolled or significant heart disease, defined as:
- Mean QT interval corrected for heart rate using Fridericia's formula (QTcF) prolongation > 470 msec (based on the average of Screening triplicate 12-lead electrocardiogram [ECG] determinations).
- Myocardial infarction or uncontrolled/unstable angina within 6 months before randomization.
- Congestive heart failure (CHF) (New York Heart Association [NYHA] Class II to IV) at Screening (see Appendix 12.3).
- Uncontrolled or significant cardiac arrhythmia (i.e., ventricular tachycardia or ventricular fibrillation), high-grade atrioventricular block, or other cardiac arrhythmias requiring anti-arrhythmic medications (except for atrial fibrillation that is well controlled with antiarrhythmic medication).
- NYHA Class III or IV Functional Classification.
- LVEF < 40% by ECHO or MUGA scan within 28 days before randomization.
- Uncontrolled hypertension (resting systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg) within 28 days before randomization.
Has a concurrent malignancy requiring active systemic or local anti-cancer treatment except for the following:
- Adequately treated non-melanoma skin cancer (squamous or basal cell cancers).
- In situ cervical cancer that has been adequately treated.
Early-stage malignancies under active surveillance or observation only, including but not limited to:
- Low-risk prostate cancer managed with active surveillance- Ductal carcinoma in situ of the breast managed with observation
- Participants of childbearing potential, who are pregnant, lactating, or intend to become pregnant or father children during the study.
- Any other significant physical and medical co-morbid conditions, including psychiatric conditions that, in the opinion of the Investigator, would impair study participation or cooperation.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Arm 1:Continued pembrolizumab with two courses of Aglatimagene besadenovec plus prodrug
Patients continue to receive pembrolizumab with two courses of Aglatimagene besadenovec plus valacyclovir
|
via intratumoral injections into lung or lymph nodes at two timepoints
Oral, for14 days following each aglatimagene besadenovec injection
every 3 weeks (Q3W) or every 6 weeks (Q6W)
|
|
アクティブコンパレータ:Arm 2: Docetaxel
Patients receive standard of care docetaxel
|
every 21 days with standard premedication
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall Survival
時間枠:From date of randomization until date of death from any cause, assessed for a minimum of 24 months
|
To evaluate whether treatment with aglatimagene besadenovec (CAN-2409) plus valacyclovir and continued pembrolizumab improves overall survival (OS) compared to standard of care (SoC) docetaxel chemotherapy, in participants with Stage IV non-squamous non-small cell lung cancer (NSCLC) whose disease has progressed following prior pembrolizumab-based platinum chemoimmunotherapy
|
From date of randomization until date of death from any cause, assessed for a minimum of 24 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Time to meaningful deterioration based on the Non-Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ) Total Score
時間枠:Baseline to Week 12
|
Defined as the time from randomization until a definitive clinically meaningful worsening in symptoms or in NSCLC-SAQ total score.
The lowest score possible is 0, and the highest score possible is 20.
Higher score indicates more severe symptoms.
|
Baseline to Week 12
|
|
Change from baseline of Total Score of NSCLC-SAQ at Week 12
時間枠:Baseline to Week 12
|
NSCLC-SAQ Total Score after Week 12 compared to baseline.
The lowest score possible is 0, and the highest score possible is 20.
Higher score indicates more severe symptoms.
|
Baseline to Week 12
|
|
Change from baseline of Global Health Status/QoL Score of EORTC-QLQ-30 at Week 12
時間枠:Baseline to Week 12
|
EORTC-QLQ-30 Global Health Status/QoL Score after Week 12 compared to baseline.
The lowest score possible is 0, and the highest score possible is 100.
Higher score indicates less severe symptoms.
|
Baseline to Week 12
|
|
Frequency of Treatment Emergent Adverse Events (TEAEs) graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)
時間枠:Baseline to 120 days after last administered dose of study drug
|
Treatment Emergent Adverse Events (TEAEs) graded per National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE)
|
Baseline to 120 days after last administered dose of study drug
|
|
Change from baseline in clinical laboratory parameters
時間枠:Baseline to 120 days after last administered dose of study drug
|
Observed values and changes from baseline for continuous clinical laboratory parameters will be summarized at each scheduled timepoint using descriptive statistics.
|
Baseline to 120 days after last administered dose of study drug
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- CAN-2409-LuTK03
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。